Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

C4 Therapeutics Q2 EPS $(0.37) Beats $(0.41) Estimate, Sales $6.463M Beat $5.240M Estimate

Author: Benzinga Newsdesk | August 07, 2025 06:13am
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $6.463 million which beat the analyst consensus estimate of $5.240 million by 23.34 percent. This is a 46.17 percent decrease over sales of $12.006 million the same period last year.

Posted In: CCCC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist